preloader icon

Apex Trader Funding (ATF) - News

Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M

Tuesday, Cartesian Therapeutics Inc (NASDAQ:RNAC) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen. It is designed to be administered as an outpatient treatment without requiring lymphodepleting chemotherapy to achieve activity with conventional CAR-T cell therapies. The trial achieved its primary endpoint with statistical significance in the pre-specified mITT efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite (MGC) score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018). MGC score aims to assess the disease severity. In addition, ...